Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.


Multitargeted agents represent the next generation of targeted therapies in solid tumors. The benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling pathways have been clinically validated in recent years in a number of solid tumor types including non-small cell lung… (More)
DOI: 10.1634/theoncologist.2008-0276

6 Figures and Tables


  • Presentations referencing similar topics